Reliable Pregnancy Testing Before Intravenous Cyclophosphamide: A Quality Improvement Study

Hayward, Kristen; Haaland, Wren; Hrachovec, Jennifer; Leu, Michael G.; Vora, Surabhi B; Clifton, Holly; Rascoff, Nanci E.; Crowell, Claudia S.

doi:10.1542/peds.2016-0378

Cited by 13 publications

(17 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…interventions, was previously used to successfully improve adolescent pregnancy screening rates. 21 Despite local contextual factors, we did not observe the magnitude of absolute reduction in unnecessary GAS pharyngitis testing for which we aimed. Cognitive bias likely played a role in unnecessary GAS pharyngitis testing.…”

Section: Figurementioning

confidence: 66%

Improving Guideline-Based Streptococcal Pharyngitis Testing: A Quality Improvement Initiative

Norton¹,

Lee²,

Harte³

et al. 2018

Pediatrics

View full text Add to dashboard Cite

show abstract

Section: Figurementioning

confidence: 66%

Improving Guideline-Based Streptococcal Pharyngitis Testing: A Quality Improvement Initiative

Norton¹,

Lee²,

Harte³

et al. 2018

Pediatrics

View full text Add to dashboard Cite

show abstract

“…Electronic health records (EHRs) can prompt providers to order pregnancy testing when prescribing cancer treatment. Hayward et al 23 found that including a pregnancy test as part of chemotherapy medication order sets in the EHR was the most effective intervention in increasing pregnancy screening rates among adolescent female patients with cancer. Use of an EHR in this manner is effective and upholds the Centers for Medicare & Medicaid Services EHR Incentive Programs' meaningful use specifications.…”

Section: System Structurementioning

confidence: 99%

Pregnancy Screening in Patients With Cancer

Gustafson¹,

Goldfrank²,

Dunson³

et al. 2018

J Natl Compr Canc Netw

View full text Add to dashboard Cite

“…Characteristics of the included studies are shown in Table 2 and summarized in Appendix B. (Chave et al, 2001;Mulryan et al, 2018) to 95.1% (Cheetham et al, 2006), pregnancy testing during treatment from 12.7% (Raguideau et al, 2015) to 100% (Hayward et al, 2016), contraception use before starting treatment from 15.7% (Uuskula et al, 2018) to 94% (Brandenburg et al, 2017), and contraception use during treatment from 1.7% (Tsur et al, 2008) to 100% (Ozyurt & Kaptanoglu, 2015).…”

Section: Risk Managementmentioning

confidence: 99%

Risk management of teratogenic medicines: A systematic review

Shroukh

Steinke

Willis

2020

Birth Defects Research

View full text Add to dashboard Cite

Aim: To systematically identify studies of implementing risk management measures when prescribing teratogenic medicines for women of childbearing age and studies reporting risk perceptions of teratogenic medications. Methods: MEDLINE, CINAHL, Scopus, EMBASE, and International Pharmaceutical Abstracts were searched. Studies were included in the risk management section if they reported any of the following risk management measures: teratogenic counseling, contraceptive counseling, pregnancy testing before starting treatment, pregnancy testing during treatment, use of contraception before starting treatment, and use of contraception during treatment. Studies were included in the perceptions section if they reported perceived teratogenic risk as numerical value. Results: Fifty-five studies were included in the risk management section and seven studies were included in the perceptions sections. Prevalence of risk management measures varied as follows: teratogenic counseling (9.5%-99.3%), contraceptive counseling (6.1%-98%), pregnancy testing before starting treatment (0%-95.1%), pregnancy testing during treatment (12.7%-100%), contraception use before starting treatment (15.7%-94%), and contraception use during treatment (1.7%-100%). A proper estimation of the teratogenic risk was reported for thalidomide (by general practitioners and obstetric/gynecologists), for etretinate (by pregnant women), and for misoprostol (by pregnant and nonpregnant women). An underestimation was reported for warfarin and retinoids (by general practitioners and obstetric/gynecologists). And overestimation was reported for thalidomide, valproate, lithium, isotretinoin, phenytoin, warfarin and etretinate by different populations. Conclusion: Considerable variation in the implementation of risk management measures when prescribing teratogenic medicines to women of childbearing age is reported in the literature. A common tendency to overestimate the risk of teratogenic medications was evident.

show abstract

Reliable Pregnancy Testing Before Intravenous Cyclophosphamide: A Quality Improvement Study

Cited by 13 publications

References 27 publications

Improving Guideline-Based Streptococcal Pharyngitis Testing: A Quality Improvement Initiative

Improving Guideline-Based Streptococcal Pharyngitis Testing: A Quality Improvement Initiative

Pregnancy Screening in Patients With Cancer

Risk management of teratogenic medicines: A systematic review

Contact Info

Product

Resources

About